In a move signaling a critical pivot for the company’s financial future, SS Innovations International has officially appointed Sarah Romano as its new Chief Financial Officer. Romano, a seasoned financial executive who previously served as the CFO of Vicarious Surgical, is set to take the reins at a time when the robotic surgery manufacturer is grappling with persistent leadership turnover and the daunting challenge of achieving sustainable growth in a capital-intensive industry.
Romano’s appointment is slated for August 3, following her departure from Vicarious Surgical on July 22. Her transition into the role marks the end of a chaotic period for SS Innovations, which has seen a revolving door of financial leadership over the past 15 months. As the company looks to secure its footing, investors and analysts are watching closely to see if Romano’s track record of fiscal discipline—honed through rigorous restructuring efforts—can provide the stability required to bring the SSi Mantra robotic system to the global stage.
The Strategic Mandate: Why Sarah Romano?
The recruitment of Sarah Romano is no coincidence; it is a calculated effort to import "turnaround expertise" into a firm facing significant liquidity headwinds. During her tenure at Vicarious Surgical, which began in April 2025, Romano was instrumental in steering the company through a period of severe financial distress.
Faced with a rapidly depleting cash runway, Romano oversaw a series of aggressive cost-cutting measures. These included the outsourcing of core robot development, significant headcount reductions, and a top-to-bottom reorganization of internal operational teams. By focusing on cash preservation and strengthening the balance sheet, she became known for her ability to navigate the "going concern" risks that often plague early-stage medtech firms.
SS Innovations finds itself in a strikingly similar position. In May 2026, the company issued a sobering disclosure to investors, noting that its existing cash resources and income from operations were insufficient to fund its business development and operational requirements for the next 12 months. Romano’s mandate is clear: she must replicate her success at Vicarious by stabilizing the company’s finances while managing the high costs associated with regulatory filings and international market expansion.
A History of Flux: The CFO Carousel
The appointment of Romano is the latest chapter in a turbulent timeline for the SS Innovations finance department. Since early 2025, the company has struggled to maintain consistency in its financial leadership, a factor that often unnerves institutional investors.
The Chronology of Turnover (2025–2026)
- April 2025: Long-time CFO Anup Sethi steps down, marking the beginning of the leadership instability.
- April 2025–July 2025: Arvind Palaniappan assumes the role on an interim basis, serving for approximately 12 weeks before resigning.
- Mid-2025: Vishwajyoti Srivastava takes over as the next interim CFO.
- September 2025: Naveen Kumar Amar is appointed as the permanent CFO, signaling a brief period of stability.
- January 2026: Amar resigns for personal reasons.
- January 2026: Milan Rao is appointed as the new permanent CFO.
- May 2026: Rao resigns after only a few months, leaving the position vacant until the announcement of Romano’s hiring.
This frequent turnover has created a vacuum of continuity that has complicated the company’s long-term financial planning. By securing an executive with a clear, established reputation like Romano, the board of directors is clearly signaling to the market that it is prioritizing institutional stability over temporary fixes.
Supporting Data: The Global Expansion Challenge
The financial pressure on SS Innovations is inextricably linked to its current market concentration. The SSi Mantra robotic system has seen moderate success in India, yet the company’s reliance on this single market is a major point of concern for analysts monitoring its growth potential.
In the first quarter of 2026, the company reported the sale of 18 SSi Mantra surgical robotic systems, with additional installations on a pay-per-use basis and system upgrades. However, the geographic distribution of this revenue is heavily skewed: 99% of the company’s total revenue for the quarter originated within India. While this speaks to the system’s effectiveness in its home market, it highlights the lack of diversification that leaves the company vulnerable to regional economic shifts.
The Regulatory Gateway: FDA 510(k) Clearance
The path to global viability rests on the company’s pending 510(k) clearance from the U.S. Food and Drug Administration, for which the company filed in December 2025. Obtaining this clearance is the primary objective of the company’s current growth strategy.
Access to the U.S. market would allow SS Innovations to move beyond its heavy reliance on India, potentially opening up a vastly more lucrative, high-margin customer base. However, the path to FDA approval is expensive, requiring extensive clinical data, rigorous documentation, and ongoing quality management compliance—all of which require a robust, well-funded finance department. Romano’s experience in managing corporate burn rates will be vital in ensuring that SS Innovations has the liquidity to survive the lengthy and often unpredictable FDA review process.
Implications for Stakeholders and the Market
The arrival of a new CFO with a specific mandate to address cash flow challenges carries several implications for the company’s future.
1. The "Turnaround" Playbook
Investors can expect Romano to scrutinize every line item of the company’s R&D and operational expenditure. Just as she did at Vicarious Surgical, Romano will likely evaluate whether the current in-house manufacturing and development processes are the most cost-effective. We may see a further pivot toward strategic partnerships, third-party manufacturing, or a more consolidated approach to product development.
2. Investor Confidence and Capital Raising
The constant leadership churn of the past year has likely hampered the company’s ability to attract long-term institutional capital. By bringing in a recognized industry veteran, SS Innovations is attempting to "reset" its narrative. If Romano can provide clear, audited financial transparency and a credible roadmap to profitability, the company may find itself in a stronger position to raise capital through equity or debt offerings later in the year.
3. Operational Focus
For the engineering and clinical teams at SS Innovations, the appointment of a fiscally conservative CFO could mean a tightening of resources. The company must balance the need for rapid innovation—necessary to keep the SSi Mantra competitive against global giants like Intuitive Surgical—with the harsh reality of its current cash constraints. Romano’s success will depend on her ability to prune non-essential costs without stifling the technical progress that the SSi Mantra needs to secure its place in the global surgical market.
Conclusion: A Critical Juncture
Sarah Romano joins SS Innovations International at a defining moment. The company has a product that is proving its utility in the Indian market, but it lacks the financial endurance to transition into a truly global player. The pattern of leadership turnover that characterized the last 15 months has left the company with a fragmented financial legacy that Romano must unify.
With the SSi Mantra’s FDA approval pending and a 12-month window to bridge its funding gap, the company has placed its faith in Romano’s ability to manage the delicate balance between innovation and insolvency. For the shareholders and employees of SS Innovations, the arrival of a new CFO is more than just an administrative update—it is the start of a final push to determine whether the company can survive the brutal, high-stakes evolution of the medical robotics sector.
As of August 3, all eyes will be on Romano’s desk. Whether she can replicate her previous success in curbing cash burn while simultaneously driving the company toward international market entry remains the defining question of the year for SS Innovations.
